Condition Directory

Non-Small Cell Lung Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Non-Small Cell Lung Cancer. Browse Non-Small Cell Lung Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced May 21, 2026, 1:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

636

Shown on this page

Local recruiting

157

Local phase groups

The trial list below is retrieved from the live ClinicalTrials.gov search API for Non-Small Cell Lung Cancer. Results on this page are currently sorted by Recently updated.

Showing 1–12 of 636 matching trials for Non-Small Cell Lung Cancer.

Indexed local directory records.

Phase distribution

Phase 1 324

Phase 2 290

Phase 3 75

Not applicable 22

Early Phase 1 5

Phase 4 2

Top locations

Houston, Texas 224 New York, New York 194 Nashville, Tennessee 193 Boston, Massachusetts 151 Los Angeles, California 130 Fairfax, Virginia 121

Top sponsors

Eli Lilly and Company 23 AstraZeneca 22 Pfizer 20 Hoffmann-La Roche 16 Memorial Sloan Kettering Cancer Center 15 Novartis Pharmaceuticals 15

Top therapies

Carboplatin 65 Pembrolizumab 65 Pemetrexed 59 Paclitaxel 40 Cisplatin 36 Nivolumab 36

Indexed official records

Open in full search

Conditions: Advanced Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Cancer, Metastatic Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer
Interventions: Chemotherapy Regimen 1, Chemotherapy Regimen 2, PF-08634404, Pembrolizumab; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 152
States / cities: Bullhead City, Arizona • Chandler, Arizona • Gilbert, Arizona + 124 more

Conditions: ICI-refractory, Non-Small Cell Lung Cancer
Interventions: SAR445877; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bladder Cancer, Cervical Cancer, Esthesioneuroblastoma, Glioblastoma Multiforme, Large Cell Neuroendocrine Carcinoma of the Lung, Medullary Thyroid Cancer, Melanoma, Merkel Cell Carcinoma, Non Small Cell Lung Cancer, Sinonasal Undifferentiated Carcinoma, Testicular Cancer
Interventions: Concurrent Radiation Therapy, Sequential Radiation therapy, Tarlatamab; Radiation · Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Tucson, Arizona • Seattle, Washington

Conditions: Carcinoma, Non-Small Cell Lung, Non Small Cell Lung Cancer, Non Small Cell Lung Carcinoma, Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer (NSCLC)
Interventions: azacytidine, carboplatin, cisplatin, durvalumab, gemcitabine, paclitaxel, pemetrexed; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-small Cell Lung Cancer
Interventions: Carboplatin, Cisplatin, Nivolumab, Pembrolizumab, Pemetrexed, Relatlimab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 45
States / cities: Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 42 more

Conditions: Advanced or Metastatic Solid Tumors, Brain Neoplasms, Differentiated Thyroid Cancer, Glioma, HGG, High Grade Glioma, LGG, Low Grade Glioma, Malignant Neoplasms, Melanoma, NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, Thyroid Cancer
Interventions: PF-07799544, PF-07799933; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 58
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Rogers, Arkansas + 28 more

Conditions: Advanced Solid Tumor, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Solid Tumor, Non-small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Recurrent Solid Tumor, Renal Pelvis Cancer, Triple Negative Breast Cancer, Urinary Bladder Neoplasm
Interventions: LY4052031; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 17
States / cities: Duarte, California • Los Angeles, California • Denver, Colorado + 12 more

Conditions: CRC, Cancer, Colon Cancer, Colorectal Adenocarcinoma, Colorectal Cancer, Lung Cancer, MESOM, Mesothelioma, Mesothelioma, Malignant, NSCLC, NSCLC, Recurrent, Non Small Cell Lung Cancer, Non-Small Cell Squamous Lung Cancer, Ovarian Cancer, Ovarian Neoplasms, Ovary Cancer, Pancreas Cancer, Pancreatic Neoplasm, Rectal Cancer, Solid Tumor, Adult
Interventions: A2B543, A2B694, xT CDx with HLA-LOH Assay; Biological · Diagnostic Test
Lead sponsor: A2 Biotherapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 12
States / cities: Gilbert, Arizona • La Jolla, California • Los Angeles, California + 9 more

Conditions: Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
Interventions: Carboplatin + Pemetrexed, Docetaxel, Gemcitabine, Gemcitabine + nab-Paclitaxel, Mavrostobart (PT199), Pembrolizumab + Carboplatin + Pemetrexed, Pemetrexed, Tislelizumab; Drug
Lead sponsor: Phanes Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 6
States / cities: Huntersville, North Carolina • Oklahoma City, Oklahoma • Nashville, Tennessee + 3 more

Conditions: Non Small Cell Lung Cancer
Interventions: Docetaxel, Telisotuzumab Vedotin; Drug · Biological
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 50
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 45 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Ivonescimab, Photon or Proton standard stereotactic body radiotherapy (SBRT); Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Non-small Cell Lung Cancer
Interventions: Exercise; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Houston, Texas

About this Non-Small Cell Lung Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Non-Small Cell Lung Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Non-Small Cell Lung Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Non-Small Cell Lung Cancer clinical trials

Filter and sort this condition

Phase distribution

Top locations

Top sponsors

Top therapies

Indexed official records

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

A Study of Ivonescimab in People With Non-Small Cell Lung Cancer

Feasibility Testing of a Dyadic Exercise Program for Patients Undergoing Thoracic Radiotherapy and Their Family Caregivers

About this Non-Small Cell Lung Cancer clinical trials directory page